Ignite Creation Date:
2024-05-05 @ 5:16 PM
Last Modification Date:
2024-10-26 @ 9:30 AM
Study NCT ID:
NCT00426855
Status:
COMPLETED
Last Update Posted:
2015-04-03
First Post:
2007-01-24
Brief Title:
Bendamustine and Bortezomib Combination Therapy in Indolent Non-Hodgkins LymphomaNHL
Sponsor:
Peter Moosmann
Organization:
Kantonsspital Aarau
Study Overview
Official Title:
Weekly Bendamustine and Bortezomib Combination Therapy in Relapsed or Refractory Indolent Non-Hodgkins Lymphoma or B-CLL A Single-Center Phase 2 Study
Status:
COMPLETED
Status Verified Date:
2015-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine whether the combination of bendamustine and bortezomib in patients with indolent Non-Hodgkins Lymphoma or Chronic Lymphocytic Leukemia is safe and tolerable
Detailed Description:
Bendamustin and bortezomib have been shown to be effective in the treatment of patients with indolent Non-Hodgkins Lymphoma NHL and Chronic Lymphocytic Leukemia CLL Both compounds appear not to be cross-resistant with prior therapy Therefore it is of interest to combine bendamustine and bortezomib in this patient population
Preliminary results from patients with multiple myeloma showed that the combination of bendamustine and bortezomib is efficacious and well tolerated However there are so far no data on this combination in patients with NHL or CLL
Preliminary results from patients with multiple myeloma showed that the combination of bendamustine and bortezomib is efficacious and well tolerated However there are so far no data on this combination in patients with NHL or CLL
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None